Female GH Optimization
85
상호작용
2
2,200
intermediate
May 17, 2026
개요
The Female GH Optimization stack pairs Ipamorelin with Tesamorelin specifically because these two peptides offer the most favorable side-effect profile for women seeking growth hormone benefits without androgenic or metabolic complications. Tesamorelin is a 44-amino-acid GHRH analog that is the only peptide in this category with full FDA approval (marketed as Egrifta for HIV-associated lipodystrophy). It stimulates pituitary GH production through the GHRH receptor, producing physiological GH pulses that closely mimic natural secretion patterns. Women naturally produce more GH than men (approximately 2x the daily output) but experience a sharper decline with age, making GH optimization particularly impactful for female physiology. Tesamorelin has been shown in clinical trials to reduce visceral adipose tissue by 15-20% without affecting subcutaneous fat — making it uniquely suited for the central adiposity pattern common in perimenopause and menopause. Its effects on IGF-1 are modest and predictable, staying within physiological ranges. Ipamorelin complements Tesamorelin by adding ghrelin-pathway stimulation without the appetite increase, cortisol elevation, or prolactin changes seen with other GH secretagogues. For women, the absence of prolactin effects is particularly important as elevated prolactin can disrupt menstrual cycles and breast tissue. The combination produces amplified GH pulses (via GHRH + GHS synergy) while maintaining clean hormonal profiles. Benefits typically observed include improved skin elasticity and thickness, reduced visceral fat, better sleep architecture, improved bone mineral density markers, and enhanced recovery from exercise. This stack is well-suited for women over 35 seeking comprehensive anti-aging and body composition benefits.
용량 프로토콜
200 mcg
1회 용량당
2,000 mcg
1회 용량당
목표 및 증거
경고
- Tesamorelin is FDA-approved (Egrifta) for HIV lipodystrophy. Off-label use for anti-aging is common but not approved. Ipamorelin remains FDA Category 2 (restricted) as of July 2026.
Comments
Sign in to join the discussion
주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.